Sharron Gargosky - Prima Biomed Insider

Prima Biomed Ltd -- USA Stock  

USD 0.01  0.00  0.00%

Chief Technical Officer

Dr. Sharron Gargosky is Chief Technical Officer of Prima Biomed Ltd. and was with Prima BioMed since August 2010. Dr. Gargosky has over 19 years experience in the biotechnology and pharmaceutical industries and has worked in senior positions in organizations that have successfully received FDA approval for orphan drugs. She is responsible for managing the clinical team working on the CVac immunotherapy cancer vaccine. Prior to joining Prima BioMed Dr. Gargosky was a member of ILMU consulting LLC where she provided project management and operational expertise on pharmaceutical drug and biologic development from early research to Phase IV Trials and the FDA approval process. Dr. Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA and Chief Scientific Officer and Senior Vice President of Corporationrationrate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products and the development of the NCE and within Medics Pharmaceuticals the successful BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management
Age: 50  Executive Since 2012  Ph.D    
61 2 8315 7003  http://www.primabiomed.com.au
Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a Ph.D in biochemistry from University of Adelaide in Australia, First Class Honors in Biochemistry from University of Adelaide, and a BS, Biochemistry, Microbiology, Immunology & Virology from University of Adelaide.

Management Efficiency

The company has return on total asset (ROA) of (15.08) % which means that it has lost $15.08 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (30.29) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.55 M in total debt with debt to equity ratio (D/E) of 21.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Prima Biomed Ltd has Current Ratio of 5.93 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology solutions in Australia. Prima Biomed Ltd (PRRUF) is traded on OTC Market in USA. It is located in Sydney, NSW and employs 31 people.

Did you try this?

Run Portfolio Suggestion Now
   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
Hide  View All  Next  Launch Portfolio Suggestion
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Prima Biomed Ltd to your portfolio

Top Management

Prima Biomed Leadership Team
Pete Meyers, Director, MBA
Russell Howard, Director, Ph.D
Tom Bloomfield, Executive
Larisa Chisholm, Executive
YueLing Wong, Chairman
Stuart Roberts, Executive
Frederic Triebel, Executive, Ph.D
Bradley Monk, Executive
Deanne Miller, Executive
Sharron Gargosky, Executive, Ph.D
Grant Chamberlain, Director
Lucy Turnbull, Chairman
Marc Voigt, CEO
Matthew Gregorowski, Executive

Stock Performance

Prima Biomed Performance Indicators